Editorial: El Periodico

• Pharmaceutical research mobilizes large sums of public and private investment.
• The cost-benefit relationship must justify its public financing and align with community health needs.
• The urgency for therapeutic solutions should not overshadow the necessary guarantees to confirm their effectiveness and possible side effects.
• A new directive on the European pharmaceutical strategy is under debate in the European Parliament.
• The current directive allows centers to apply experimental therapies bypassing some steps of the centralized authorization system.
• The popular and liberal parliament support an amendment to limit hospital exemption.

Conclusion: It is imperative to maintain the necessary balance ensuring that the benefits of therapies reach patients without putting them at risk, regardless of existing commercial or economic conflicts.

---